Reuters logo
9 个月前
BRIEF-Vascular Biogenics study to treat recurrent thyroid cancer met its min goal
2016年11月29日 / 下午12点57分 / 9 个月前

BRIEF-Vascular Biogenics study to treat recurrent thyroid cancer met its min goal

Nov 29 (Reuters) - Vascular Biogenics Ltd -

* Press release - VBL Therapeutics announces overall survival data for VB-111 monotherapy in phase 2 study for recurrent thyroid cancer

* Study met its primary endpoint, demonstrating disease stabilization and safety, along with a dose-response

* Based on current data, may expand program to additional indications, such as thyroid cancer

* New data show dose-response, evidence overall survival benefit in cohort of patients treated with multiple therapeutic doses of VB-111 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below